Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Beijing SL Pharmaceutical Co Ltd
Net Income (Common)
Beijing SL Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
B
|
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
|
Net Income (Common)
¥284.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-7%
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
35%
|
CAGR 10-Years
50%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.3B
|
CAGR 3-Years
61%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
See Also
What is Beijing SL Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
284.9m
CNY
Based on the financial report for Mar 31, 2024, Beijing SL Pharmaceutical Co Ltd's Net Income (Common) amounts to 284.9m CNY.
What is Beijing SL Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-7%
Over the last year, the Net Income (Common) growth was -24%. The average annual Net Income (Common) growth rates for Beijing SL Pharmaceutical Co Ltd have been -10% over the past three years , -14% over the past five years , and -7% over the past ten years .